Gallium

Appia Announces Appointment of Dr. Gary Delaney as Consultant and Advisor to The Board of Directors

Retrieved on: 
Tuesday, October 18, 2022
Brock University, FSE, API, Doctor of Philosophy, Teck Resources, SGS, University, Geology, Research, Carleton University, Energy, Company, Mining, Gallium, Geological Survey of Canada, Adolphe Appia, CSE, Sullivan Mine, Canadian Securities Exchange, Leadership, News, Ministry, Forward-looking statement, Government, Fission Uranium Corp., Otherside, Rare-earth element, Oil, Security (finance), Territory

in geology from Brock University, St. Catharines, Ontario; and a Ph.D. in geology from the University of Western Ontario, London, Ontario.

Key Points: 
  • in geology from Brock University, St. Catharines, Ontario; and a Ph.D. in geology from the University of Western Ontario, London, Ontario.
  • Between 1981 and 1985 Dr. Delaney, worked as a research geologist for Cominco Ltd. at the Sullivan Mine in Kimberley, British Columbia.
  • In 1998, Dr. Delaney became Director of Northern Geological Survey Branch of the SGS and in 2010, Chief Geologist.
  • Dr. Delaney has been granted 200,000 share purchase options exercisable at $0.60 per share for five years.

Outlook on the Monolithic Microwave IC Global Market to 2030 - Players Include ON Semiconductor, Texas Instruments, Analog Devices and Northrop Grumman - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 20, 2022
Technology, Semiconductor, Adoption, Growth, Component, CAGR, APAC, Monolithic microwave integrated circuit, Geography, MMIC, Gallium, US, Wood-plastic composite, Consumer electronics, Marketing

Global Monolithic Microwave IC Market, by Component, 2021 (US$ Mn)

Key Points: 
  • Global Monolithic Microwave IC Market, by Component, 2021 (US$ Mn)
    Based on component, power amplifiers have the largest market revenues.
  • Global Monolithic Microwave IC Market, by Material Type, 2021 (US$ Mn)
    Based on material type, gallium arsenide market had the largest market revenues.
  • Global Monolithic Microwave IC Market, by Technology Protocol, 2021 (US$ Mn)
    Based on technology protocol, metal-semiconductor field-effect transistor had the largest market revenues.
  • Global Monolithic Microwave IC Market, by Geography, 2021 (US$ Mn)
    Based on geography, Asia Pacific market had the largest market revenues.

Solar Panel Recycling Market to Reach $302.9 Million by 2027 at a CAGR of 18.32%

Retrieved on: 
Thursday, October 20, 2022
Adoption, Method, PV, Dangerous, GHG, CAGR, Silicon, Research, Recycling, Collection, Cadmium, R, Silver, Industry, Gallium, Aluminium, Copper, EOL, COVID-19, Lead, Renewable energy, Growth

DUBLIN, Oct. 20, 2022 /PRNewswire/ --The "Solar Panel Recycling Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 20, 2022 /PRNewswire/ --The "Solar Panel Recycling Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global solar panel recycling market size reached US$ 110.4 Million in 2021.
  • Looking forward, the publisher expects the market to reach US$ 302.9 Million by 2027, exhibiting a CAGR of 18.32% during 2021-2027.
  • This represents one of the key factors stimulating the need for solar panel recycling methods to minimize human health risks and ensure end-of-life (EoL) management.

Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

Retrieved on: 
Monday, October 17, 2022
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Colon, Therapy, Neoplasm, EMA, Hyponatremia, NASDAQ, Antibody, Lymphocytopenia, SD, University, Abdominal distension, Primary sclerosing cholangitis, Association, Pseudomyxoma peritonei, CEO, Toxic leukoencephalopathy, University of California, San Francisco, Mesothelioma, UCSF, Database administrator, Population, Data, HIV disease progression rates, Cancer, Private Securities Litigation Reform Act, TRT, Department, Literature, Peptide, FDA, Isotope, RECIST, FAP, EANM, Kidney, Research, Security (finance), Cell, Trial of the century, Gallium, U.S. Securities and Exchange Commission, Radiation, Clovis Oncology, View, Sarcoma, Patient, Radiology, Gallbladder cancer, Drug discovery, Molecular Therapy, Toxicity, Safety, Biomedicine, Pharmaceutical industry, Medical imaging, Pharmacokinetics

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation at the 35th Annual European Association of Nuclear Medicine Congress (EANM) detailing updated Phase 1 data from the Clovis Oncology-sponsored Phase 1/2 LuMIERE clinical study (NCT04939610) investigating the safety, pharmacokinetics, dosimetry, and preliminary anti-tumor activity of its targeted radiotherapy candidate, FAP-2286 labeled with lutetium-177 (177Lu-FAP-2286).

Key Points: 
  • Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation at the 35th Annual European Association of Nuclear Medicine Congress (EANM) detailing updated Phase 1 data from the Clovis Oncology-sponsored Phase 1/2 LuMIERE clinical study (NCT04939610) investigating the safety, pharmacokinetics, dosimetry, and preliminary anti-tumor activity of its targeted radiotherapy candidate, FAP-2286 labeled with lutetium-177 (177Lu-FAP-2286).
  • The Phase 1 portion of the LuMIERE study is evaluating the safety of the investigational therapeutic agent 177Lu-FAP-2286 to identify the recommended Phase 2 dose and schedule.
  • The LuMIERE trial is the first prospective trial of a FAP peptide targeted radionuclide therapy and is currently in the dose escalation phase.
  • Updated results from the Phase 1 portion of the ongoing Phase 1/2 LuMIERE study found treatment-emergent adverse events (TEAEs) were mostly Grade 1 and 2 across cohorts.

mPower Technology Selected by OneWeb for Innovation Program Demonstration

Retrieved on: 
Tuesday, October 18, 2022
Silicon, MPower, PV, Technology, Gallium, VP, OneWeb, LEO, Renewable energy, Communications satellite

ALBUQUERQUE, N.M., Oct. 18, 2022 /PRNewswire/ -- Innovative solar technology company, mPower Technology, Inc., announced today that its DragonSCALES™ solar modules have been selected by global space-based communications company, OneWeb, for an innovation program demonstration. The project will kick off this year. The objective of this demonstration is to evaluate DragonSCALES silicon solar module performance under representative LEO (low-Earth orbit) mission conditions.

Key Points: 
  • ALBUQUERQUE, N.M., Oct. 18, 2022 /PRNewswire/ -- Innovative solar technology company, mPower Technology, Inc. , announced today that its DragonSCALES solar modules have been selected by global space-based communications company, OneWeb , for an innovation program demonstration.
  • The objective of this demonstration is to evaluate DragonSCALES silicon solar module performance under representative LEO (low-Earth orbit) mission conditions.
  • mPower Technology designed DragonSCALES to meet the specific requirements of space applications, including low-Earth orbit environments.
  • mPower Technology is shaping the future of solar power with a revolutionary new technology called DragonSCALES, a completely flexible, interconnected mesh of miniature solar cells.

Telix Partnership Expands GE Healthcare Immuno-Diagnostics Offering to the Global Clinical Research Market

Retrieved on: 
Monday, October 17, 2022
LinkedIn, Congress, Australian Securities Exchange, Head, ICI, Lactic acid, Neoplasm, GE Healthcare, Thomas Edison, TGA, Association, Advertising, Cancer, Carbonic anhydrase, NYSE, Regulation of tobacco by the U.S. Food and Drug Administration, HIV disease progression rates, Company, Marketing, Industry, Nuclear medicine, Diversified Pharmaceutical Services, European Association for the Study of the Liver, Disclosure, FDA, Risk, Review, EANM, Research, Multimedia, Immunotherapy, Degenerative disease, Gallium, Veni, vidi, vici, PD-1, Ecosystem, Oxygen, View, ASX, Patient, European Association of Nuclear Medicine, Partnership, Food, TLX, United Kingdom, PET, Forward-looking statement, JAMA Network Open, Medical imaging, Pharmaceutical industry, Animal, Media, Telix

TLX250-CDx and [18F]-FLac complement GE Healthcare Pharmaceutical Diagnostics' pipeline of investigational non-invasive [18F]-CD8 and[18F]-Granzyme-B imaging tracers for use by pharmaceutical companies in clinical trials, with the potential to predict and monitor response to immunotherapy.

Key Points: 
  • TLX250-CDx and [18F]-FLac complement GE Healthcare Pharmaceutical Diagnostics' pipeline of investigational non-invasive [18F]-CD8 and[18F]-Granzyme-B imaging tracers for use by pharmaceutical companies in clinical trials, with the potential to predict and monitor response to immunotherapy.
  • Sanka Thiru, Global Business Leader, Immuno-Oncology, at GE Healthcare's Pharmaceutical Diagnostics business, said: "This partnership expands our pharmaceutical services offering, including our toolbox of investigational PET imaging diagnostics.
  • Telix and GE Healthcare will explore validation of [18F]-FLac for use in GE Healthcare's FASTlab, an automated PET radiochemistry synthesiser, widely used for onsite production of FDG6 and other PET tracers.
  • The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates all rights reserved.

Telix Partnership Expands GE Healthcare Immuno-Diagnostics Offering to the Global Clinical Research Market

Retrieved on: 
Monday, October 17, 2022
LinkedIn, Congress, Australian Securities Exchange, Head, ICI, Lactic acid, Neoplasm, GE Healthcare, Thomas Edison, TGA, Association, Advertising, Cancer, Carbonic anhydrase, NYSE, Regulation of tobacco by the U.S. Food and Drug Administration, HIV disease progression rates, Company, Marketing, Industry, Nuclear medicine, Diversified Pharmaceutical Services, European Association for the Study of the Liver, Disclosure, FDA, Risk, Review, EANM, Research, Immunotherapy, Degenerative disease, Gallium, Veni, vidi, vici, PD-1, Ecosystem, Oxygen, ASX, Patient, European Association of Nuclear Medicine, Partnership, Food, TLX, United Kingdom, PET, Forward-looking statement, JAMA Network Open, Medical imaging, Pharmaceutical industry, Animal, Media, Telix

Sanka Thiru, Global Business Leader, Immuno-Oncology, at GE Healthcare's Pharmaceutical Diagnostics business, said: "This partnership expands our pharmaceutical services offering, including our toolbox of investigational PET imaging diagnostics.

Key Points: 
  • Sanka Thiru, Global Business Leader, Immuno-Oncology, at GE Healthcare's Pharmaceutical Diagnostics business, said: "This partnership expands our pharmaceutical services offering, including our toolbox of investigational PET imaging diagnostics.
  • Telix and GE Healthcare will explore validation of [18F]-FLac for use in GE Healthcare's FASTlab, an automated PET radiochemistry synthesiser, widely used for onsite production of FDG6 and other PET tracers.
  • The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates all rights reserved.
  • CONTACT: Telix Investor Relations: Ms. Kyahn Williamson, Telix Pharmaceuticals Limited, SVP Corporate Communications and Investor Relations, Email: [email protected] ; GE Healthcare Media Contact: Debbie Leven / [email protected] , +44 7785 456999

GE Healthcare Introduces Omni Legend: A First-of-its-Kind All-Digital PET/CT System to Drive Efficiency, Enhance Diagnostics, and Deliver on Precision Medicine

Retrieved on: 
Sunday, October 16, 2022
Oncology, Health, Medical Devices, Neurology, Radiology, Cardiology, Biotechnology, Omni, LinkedIn, Efficiency, Protocol, Instagram, LED, Thomas Edison, CT scan, Association, CEO, Health, Calibration, Gallium, Challenge, Dynamics, Precision, News, NEMA, Cardiology, NYSE, GE Healthcare, Twitter, Annual general meeting, Artificial intelligence, Software, Nuclear medicine, CE, European Association of Nuclear Medicine, Gallium-68 generator, Movement, Deep learning, Diagnosis, EANM, Maimonides, Collection, Technology, Molecular imaging, Technion Faculty of Electrical Engineering, Ecosystem, Artifact, Sale, BGO, Technion – Israel Institute of Technology, Patient, Insight, CT, Rambam Health Care Campus, PET, Medical imaging, Medical device, Pharmaceutical industry, Facebook, PET/CT

At the European Association of Nuclear Medicine (EANM) Annual Meeting, GE Healthcare proudly introduces Omni Legendi, the first system on its all-new, all-digital PET/CT platform.

Key Points: 
  • At the European Association of Nuclear Medicine (EANM) Annual Meeting, GE Healthcare proudly introduces Omni Legendi, the first system on its all-new, all-digital PET/CT platform.
  • For more information about GE Healthcares new Omni PET/CT platform and Omni Legend system, visit gehealthcare.com .
  • GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE).
  • ii Omni Legend 32 cm has up to 2.2 increase in system sensitivity as compared to Discovery MI 25 cm.

Solar Panel Recycling Market Report 2022: Rising Solar Panel Sales & Adoption of Renewable Energy Fueling Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 11, 2022
Alternative Energy, Energy, Adoption, Method, PV, Dangerous, GHG, CAGR, Silicon, Research, Recycling, Collection, Cadmium, R, Silver, Industry, Gallium, Aluminium, Copper, EOL, COVID-19, Lead, Renewable energy, Growth

The "Solar Panel Recycling Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Solar Panel Recycling Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global solar panel recycling market size reached US$ 110.4 Million in 2021.
  • Looking forward, the publisher expects the market to reach US$ 302.9 Million by 2027, exhibiting a CAGR of 18.32% during 2021-2027.
  • The rising sales of solar panels worldwide due to the increasing adoption of renewable energy sources is resulting in a massive amount of waste streams in landfills every year.

EANM Presentations to Showcase New Data and Developments in Telix's Theranostics Pipeline

Retrieved on: 
Monday, October 10, 2022
LinkedIn, Carbonic anhydrase, Congress, Nuclear medicine, Australian Securities Exchange, ASX, Radio, Institute, Regulation of tobacco by the U.S. Food and Drug Administration, Radboud University Medical Center, Patient, PSMA, European Association of Nuclear Medicine, EANM, Research, Cancer, Degenerative disease, Food, TGA, Gallium, Company, Department, Association, Breast cancer, TLX, Prostate cancer, Head, European Association of Urology, Department of Urology, University of Virginia, FDA, Kidney, External beam radiotherapy, Pharmaceutical industry, Medical imaging, Vaccine, Animal, Telix, Urology

Our sponsored symposium provides an insight to the advancements in imaging, surgery and patient management for the genitourinary oncology field.

Key Points: 
  • Our sponsored symposium provides an insight to the advancements in imaging, surgery and patient management for the genitourinary oncology field.
  • The breadth of our innovative theranostic pipeline is demonstrative of our commitment and progress towards advancing nuclear medicine across a range of indications."
  • EANM presentation details are as follows:
    Chairperson: Professor Wolfgang Fendler- Vice Chair, Clinic for Nuclear Medicine, EssenUniversity Hospital, Essen, Germany.
  • -Professor JochenWalz - Head of the Department of Urology at the Institut Paoli-Calmettes Cancer Centre, Marseille, France.